BD posts healthy global, U.S. Q4 revenues

By The Science Advisory Board staff writers

Becton Dickinson (BD) has reported worldwide fourth quarter revenues of $4.8 billion (end-September 30), up 4.4% compared to the same period in 2019. U.S. revenues increased 7.4%, to $2.7 billion.

The company's COVID-19 testing sales totaled more than $440 million for the quarter, it said.

Its Life Sciences segment posted revenues of $1.5 billion, up 31.2% compared to the same period last year. However, the company's Medical segment posted worldwide revenues of $2.3 billion, down 4.9% from 2019, and its Interventional segment revenues decreased 3.4% compared to 2019, at $978 million, which BD attributed in part to the impact of COVID-19.


Copyright © 2020 scienceboard.net
 

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a Scienceboard.net password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?